The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 ...

New data show the machine learning algorithms may be used to detect PCWP elevation, aiding in assessment of heart failure with preserved ejection ...

Heart failure with preserved ejection fraction, or HFpEF, occurs when the heart pumps normally but is too stiff to fill properly. Current research suggests that HFpEF occurs when chronic medical ...

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an ...